Tag: Ruud Dobber

  • Over 67 million screenings – AstraZeneca’s ‘Healthy Heart Africa’ celebrates 10 years of transforming Noncommunicable Disease (NCD) care

    Over 67 million screenings – AstraZeneca’s ‘Healthy Heart Africa’ celebrates 10 years of transforming Noncommunicable Disease (NCD) care

    HHA aims to improve access to timely diagnosis and treatment, reducing the burden of this disease across communities

    AstraZeneca’s flagship health equity programme – Healthy Heart Africa (HHA), marks its 10th anniversary, celebrating successfully taking over 67 million blood pressure screenings and a decade of action against non-communicable diseases across Africa.

    Hypertension is a leading risk factor for cardiovascular diseases and accounts for a significant portion of noncommunicable disease (NCD) deaths globally. In Africa, over 27% of adults live with hypertension[1], far above the global average.

    Since its launch, HHA has conducted over 67 million blood pressure screenings, trained over 11,700 healthcare workers, and activated over 1,550 healthcare facilities across nine African countries in Kenya, Ethiopia, Ghana, Uganda, Côte d’Ivoire, Senegal, Rwanda, Nigeria and Tanzania including the Island of Zanzibar. These efforts have significantly improved access to hypertension diagnosis and treatment, saving countless lives.

    Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: “Healthy Heart Africa epitomises AstraZeneca’s commitment to equitable healthcare. In a decade, we’ve empowered millions to manage their heart health. Now, we’ve expanded to tackle chronic kidney disease, ensuring greater resilience in health systems across the continent.”

    The programme has started addressing chronic kidney disease (CKD), which is closely linked to hypertension and affects 15.8% of Africans.[2] Early detection and management are critical, as CKD often progress silently. HHA aims to improve access to timely diagnosis and treatment, reducing the burden of this disease across communities.

    This commemoration sets the stage for the upcoming World Health Organization’s High-Level Meeting on NCDs[3], reinforcing the urgency of collective action. One facet of the programme’s success is built on strong partnerships with governments, NGOs, and community leaders to deliver culturally tailored interventions.

    Helen McGuire, Global Program Leader, PATH, added: “Working on the Healthy Heart Africa (HHA) programme with AstraZeneca has been truly transformative. Seeing the scale-up and institutionalisation of integrated and expanded NCD services, particularly in countries like Ghana, has been immensely rewarding. The introduction of NCD indicators into national health information systems represents a major milestone, enabling better planning, resource allocation, and outcome monitoring.”

    Ministries of Health across Africa have championed HHA’s integration of hypertension care into national policies, ensuring sustainability and local ownership.

    Permanent Secretary Uganda Ministry of Health, Dr Diana Atwine Kanzira, said: “In Uganda, our partnership with Healthy Heart Africa has been instrumental in strengthening our response to non-communicable diseases (NCDs), now a major health challenge across Africa. Through this collaboration, we have raised awareness on risk factors, enhanced early detection, linked patients to care, and built the capacity of healthcare workers. By integrating hypertension data into our national health system and advancing digitalization, we are ensuring a seamless patient pathway, enabling progress tracking, and delivering life-saving care to our people.”

    With its proven model – the Healthy Heart Africa programme aims to expand to new regions, integrating climate-resilient healthcare solutions and prioritising early detection to prevent disease progression. Through such innovative partnerships, the programme aims to deliver care to those most in need.

  • Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa

    Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa

    The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension

    Broader range of non-communicable diseases targeted including chronic kidney disease; Programme growing across Africa, 54 million blood pressure screenings to date.

    AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease. The expanded programme will also launch in Egypt, reaching even more patients across the continent.

    At the 77th World Health Assembly (WHA) during an event co-hosted with the Ministry of Health for Uganda, AstraZeneca announced that the expanded Healthy Heart Africa programme will be operational in Côte d’Ivoire, Egypt, Ethiopia, Ghana, Kenya, Nigeria, Rwanda, Senegal and Uganda by the end of 2025.

    Launched in 2014, Healthy Heart Africa was established to address the increasing burden of cardiovascular diseases in Africa. The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension; providing health education and access to early screening and treatment; and delivering training to healthcare providers. This supports health system resilience by relieving the social and economic burden arising from late-stage treatment and care of cardiovascular and related diseases.

    Over the past decade, the programme has conducted more than 54 million blood pressure screenings and trained more than 11,400 healthcare workers. By March 2024, the programme achieved its initial ambition to reach 10 million people with elevated blood pressure, nearly two years ahead of target.

    HE Dr Jean Ruth Aceng Ocero, Minister of Health for The Republic of Uganda, said:  “As we confront the burden of non-communicable diseases in Uganda, which account for 36% of deaths and 81,300 annual mortalities it is imperative to strengthen our health systems. With a 21% probability of premature mortality from NCDs, resilient health systems are crucial for early detection and effective management.”

    HE Dr Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, said: “The rising burden of non-communicable diseases (NCDs) in Africa, which have increased from 24% in 2000 to 37% in 2019 of all deaths, highlights the urgent need for comprehensive and coordinated action. Supporting Member States to integrate NCD prevention and control into primary healthcare and strengthen multisectoral coordination on NCDs are among the priority interventions for the African CDC.”

    Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “The public and private sectors must work hand in hand to address the escalating burden of NCDs and ensure more equitable and sustainable health outcomes for patients across Africa and beyond. Heart and kidney health are often interconnected, and with earlier diagnosis, intervention and treatment of cardiorenal diseases, we have a tremendous opportunity to prevent life-threatening complications, and reduce the economic and environmental impact of disease across the continent.”

    HE Dr Khaled Abdel Ghaffar, Minister of Health and Population for Egypt, said: “With the links between climate change and noncommunicable diseases like heart and kidney disease, it is becoming increasingly clear that we must act urgently to adapt our health systems to deal with this reality. Egypt is proud to be joining the Healthy Heart Africa program as part of our steadfast commitment to improving the health and well-being of all Egyptians. Through the signed Letter of Intent, we will be able to improve CKD public awareness, enhance early screening and diagnosis, support training for our HCPs, digitalize CKD healthcare management and update our local management protocols in line with the latest global standards.”

    At the event, global leaders in NCD care, including Ministers of Health for Uganda, Ethiopia and Egypt, as well as high-level representatives from the Africa CDC, the World Health Organization, PATH, Amref and patient advocacy groups, committed to tackle the growing burden of NCDs in Africa, emphasising the importance of early detection, evidence-based treatments, and the effective implementation of public-private partnerships such as Healthy Heart Africa.

    AstraZeneca reinforced its focus on taking a public-private partnership approach to deliver Healthy Heart Africa’s goals by signing Memorandums of Understanding with the Ministries of Health from Egypt, Uganda, and Ghana. The programme supports Sustainable Development Goal (SDG) 3 & 4 to reduce by one-third premature mortality from NCDs through prevention and treatment by 2030.